RORC and cancer: RORγ bound to and repressed the PDL1 gene promoter and blunted PDL1/ITGB6/FAK-dependent nuclear translocation of STAT3, proposing RORγ agonism as a novel anti-cancer approach in conjunction with checkpoint Abs.